Brief: Merus' Zenocutuzumab Granted Breakthrough Therapy Designation By U.S. FDA

Merus NV

05/07/2023 21:25

July 5 (Reuters) - Merus NV  MRUS.O :
    * ZENOCUTUZUMAB (ZENO) GRANTED SECOND BREAKTHROUGH THERAPY
DESIGNATION BY THE U.S. FOOD & DRUG ADMINISTRATION
    * MERUS NV - ZENO GRANTED BTD FOR TREATMENT OF NRG1+
NON-SMALL
CELL LUNG CANCER
    * MERUS NV - PLANS TO PROVIDE A CLINICAL UPDATE ON ZENO IN
NRG1+
CANCER AT A MAJOR MEDICAL CONFERENCE IN 2023
    * MERUS NV - PLANS TO PROVIDE INITIAL CLINICAL DATA ON ZENO
IN
CRPC IN SECOND HALF OF 2023

Source text for Eikon:  ID:nGNXb9mtVt 
Further company coverage:  MRUS.O 

 ((Reuters.Briefs@thomsonreuters.com;))